PDF(Pubmed)
Abstract：
Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still a potential means of eradicating lung cancer, patients with advanced lung cancer usually miss the best chance for surgical treatment, and even after surgical resection patients may still experience tumor recurrence. Additionally, chemotherapy, the mainstay of treatment for patients with advanced lung cancer, has the potential to be chemo-resistant, resulting in poor clinical outcomes. The emergence of liquid biopsies has garnered considerable attention owing to their noninvasive nature and the ability for continuous sampling. Technological advancements have propelled circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and tumor-associated antigens (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, tumor metabolites, TAAs and TEPs. Furthermore, we expound on the practical applications of liquid biopsies, including early diagnosis, treatment response monitoring, prognostic evaluation, and recurrence monitoring in the context of lung cancer.
摘要：
肺癌是全球最普遍的癌症，对人类福祉构成重大威胁。由于缺乏有效、准确的早期诊断方法,许多患者被诊断为晚期肺癌。尽管手术切除仍然是根除肺癌的潜在手段，晚期肺癌患者通常错过手术治疗的最佳机会，即使在手术切除后，患者仍可能经历肿瘤复发。此外,化疗,晚期肺癌患者的主要治疗方法，有可能产生化学抗性，导致不良的临床结果。液体活检的出现由于其非侵入性和连续采样的能力而引起了相当大的关注。技术进步推动了循环肿瘤细胞（CTC），循环肿瘤DNA（ctDNA），细胞外囊泡（EV），肿瘤代谢物，肿瘤培养的血小板（TEP），和肿瘤相关抗原（TAA）作为关键的液体活检生物标志物，为肺癌的早期诊断和预后评估提供了有趣和令人鼓舞的结果。这篇综述概述了肺癌液体活检中使用的分子生物标志物和检测方法。包括CTC，ctDNA,非编码RNA(ncRNA)，电动汽车,肿瘤代谢物，TAAs和TEP。此外，我们阐述了液体活检的实际应用，包括早期诊断,治疗反应监测，预后评估，和肺癌复发监测。
